vs
Side-by-side financial comparison of Anbio Biotechnology (NNNN) and TRINITY BIOTECH PLC (TRIB). Click either name above to swap in a different company.
Anbio Biotechnology is a specialized in vitro diagnostic (IVD) biotechnology enterprise that develops, manufactures and markets a wide range of rapid testing solutions. Its product portfolio covers infectious disease detection, cardiovascular marker tests, food safety screening kits and supporting diagnostic tools, serving clinical labs, healthcare facilities and supervision bodies across global markets.
Trinity Biotech PLC develops, manufactures and markets diagnostic test kits and systems for clinical laboratories and point-of-care settings. Its product portfolio covers diabetes management, infectious diseases, cardiac health, autoimmune disorders and coagulation, with core markets across North America, Europe and emerging economies.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 24 | — | $30.5M | ||
| Q3 23 | — | $15.7K | ||
| Q2 23 | — | $15.4K | ||
| Q1 23 | — | $15.7K | ||
| Q2 22 | — | $37.2M | ||
| Q1 22 | — | $25.6K |
| Q2 24 | — | $-10.1M | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — | ||
| Q2 22 | — | $-22.0M | ||
| Q1 22 | — | — |
| Q2 24 | — | 36.8% | ||
| Q3 23 | — | 2.1% | ||
| Q2 23 | — | 36.2% | ||
| Q1 23 | — | 38.2% | ||
| Q2 22 | — | 37.0% | ||
| Q1 22 | — | 42.6% |
| Q2 24 | — | -23.2% | ||
| Q3 23 | — | -51.8% | ||
| Q2 23 | — | -12.0% | ||
| Q1 23 | — | -7.8% | ||
| Q2 22 | — | -5.0% | ||
| Q1 22 | — | 12.0% |
| Q2 24 | — | -33.0% | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — | ||
| Q2 22 | — | -59.0% | ||
| Q1 22 | — | — |
| Q2 24 | — | — | ||
| Q3 23 | — | $-23.50 | ||
| Q2 23 | — | $-28.60 | ||
| Q1 23 | — | $-50.00 | ||
| Q2 22 | — | — | ||
| Q1 22 | — | $7.10 |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
